Weld Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Weld Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-963	Closed	-$207K	–	390
2021 Q1	$207K	Buy	+963	New	+$212K	0.09%	292
2020 Q2	–	Sell	-8,864	Closed	-$2.11M	–	644
2020 Q1	$2.11M	Buy	+8,864	New	+$2.03M	1.08%	1
2019 Q4	–	Sell	-7,134	Closed	-$1.21M	–	954
2019 Q3	$1.21M	Buy	+7,134	New	+$1.26M	0.22%	117
2019 Q2	–	Sell	-8,675	Closed	-$1.6M	–	940
2019 Q1	$1.6M	Buy	+8,675	New	+$1.6M	0.29%	80

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Weld Capital Management's VRTX Position: Q2 2021 in Review

Weld Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2021, closing a stake of 963 shares — an estimated $207K sold.

Weld Capital Management first reported a position in VRTX in Q1 2019 and held it in 4 quarters. The position peaked at $2.11M in Q1 2020. 978 funds tracked by Wall St. Rank hold VRTX as of Q2 2021.

Weld Capital Management reported no remaining Vertex Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Weld Capital Management sold 963 Vertex Pharmaceuticals shares in Q2 2021, an estimated $207K.
Weld Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2019 and held it in 4 quarters.
Weld Capital Management's Vertex Pharmaceuticals position peaked at $2.11M in Q1 2020.
978 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2021.

Based on Weld Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.